A Phase 1 Randomized, Blinded, Placebo-controlled Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus
Latest Information Update: 16 Dec 2022
Price :
$35 *
At a glance
- Drugs MEDI-6570 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors AstraZeneca; MedImmune
- 07 Nov 2022 Results assessing response Biomarkers and Signaling Pathways Associated With the LOX-1 Blockade by MEDI6570 in Type 2 Diabetes presented at the American Heart Association Scientific Sessions 2022
- 17 May 2021 Results presented at the 70th Annual Scientific Session of the American College of Cardiology
- 21 Aug 2020 Status changed from active, no longer recruiting to completed.